CA2229123A1 — Pharmaceutical agents
Assigned to Eli Lilly and Co · Expires 1998-08-11 · 28y expired
What this patent protects
The present invention provides a method of inhibiting glucose metabolism deterioration in a mammal by administering a substituted aminopyrimidine having the Formula wherein R1, R2, and R3 are, independently, hydrogen, halogen, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkyl, or C3-C…
USPTO Abstract
The present invention provides a method of inhibiting glucose metabolism deterioration in a mammal by administering a substituted aminopyrimidine having the Formula wherein R1, R2, and R3 are, independently, hydrogen, halogen, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkyl, or C3-C5-cycloalky; R4 is hydrogen, formyl, acetyl, propionyl or butyryl; provided that R1, R2 and R3 are not all hydrogen at the same time; or a pharmaceutically acceptable salt or solvate thereof.
Drugs covered by this patent
- Velsipity (Etrasimod Arginine) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.